Achillion is not likely to develop an all-oral Hep C therapy on its own, which is why the company needs to be as deal friendly as possible. "None of the major players in the Hep C field can lay claim today to having everything they need," said Kishbauch, explaining why he thinks Hep C deal activity is about to accelerate. He's right. The big Hep C players -- Roche, Merck, Vertex, Bristol-Myers Squibb ( BMY) -- could all benefit from bringing in new drugs. It remains to be seen, however, if Achillion has what these guys want. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com.